Wohl & Fruchter LLP is investigating whether the proposed sale of Nuvalent, Inc. to GSK for $124 per share is fair to shareholders, noting this price is below several Wall Street analysts' targets, which range from $126 to $158 per share. The firm is examining if Nuvalent's board acted in shareholders' best interests and fully disclosed all material information and conflicts related to the deal. Shareholders concerned about the sale price are encouraged to contact the law firm for a free consultation. This investigation highlights potential shareholder dissatisfaction with the sale terms and could impact the transaction's progress.
Biotech companies are increasingly adopting a dual-track approach by preparing for IPOs while also engaging with potential acquirers, as investors have become more selective since the pandemic boom. Big Pharma is actively seeking to replenish drug pi...
Halper Sadeh LLC is investigating the sales of Avanos Medical, Nuvalent, XOMA Royalty, and TruBridge for possible breaches of federal securities laws and fiduciary duties to shareholders. The firm suggests insiders may gain financial benefits not ava...
